Protective effect of INI-0602, a gap junction inhibitor, on dopaminergic neurodegeneration of mice with unilateral 6-hydroxydopamine injection

Journal of Neural Transmission

Volumn 121, Issue 11, 2014, Pages 1349-1355

  Suzuki, Hiromi ^a   Ono, Kenji ^a   Sawada, Makoto ^a  

^a NAGOYA UNIVERSITY   (Japan)

Author keywords

6 Hydroxydopamine; Dopaminergic protection; Gap junction inhibitor; INI 0602; Microglia; Parkinson s disease

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; INI 0602; INTERLEUKIN 1BETA; NEUROPROTECTIVE AGENT; OXIDOPAMINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; ADRENERGIC RECEPTOR STIMULATING AGENT; AIF1 PROTEIN, MOUSE; CALCIUM BINDING PROTEIN; DOPAMINE; FUSED HETEROCYCLIC RINGS; INI-0602; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; EXPERIMENTAL PARKINSONISM; FLUORESCENCE; GAP JUNCTION; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA; ANALYSIS OF VARIANCE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEMISPHERIC DOMINANCE; METABOLISM; NEURODEGENERATIVE DISEASES; PATHOLOGY;

ADRENERGIC AGENTS; ANALYSIS OF VARIANCE; ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CALCIUM-BINDING PROTEINS; DISEASE MODELS, ANIMAL; DOPAMINE; FUNCTIONAL LATERALITY; GENE EXPRESSION REGULATION; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; INTERLEUKIN-1BETA; MALE; MICE; MICE, INBRED C57BL; MICROFILAMENT PROTEINS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; TYROSINE 3-MONOOXYGENASE;

EID: 84925785725     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-014-1209-z     Document Type: Article

References (26)

1. Akiyama H, McGeer PL (1989) Microglial response to 6-hydroxydopamine- induced substantia nigra lesions. Brain Res 489:247-253. doi:10.1016/0006-8993(89)90857-3
2. Barger SW, Basile AS (2001) Activation of microglia by secreted amyloid precursor protein evokes release of glutamate by cystine exchange and attenuates synaptic function. J Neurochem 76:846-854. doi:10.1046/j.1471-4159.2001.00075.x
3. Block ML, Hong JS (2007) Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans 35(Pt5):1127-1132. doi:10.1042/BST0351127
4. Calabresi P, Galletti F, Saggese E, Ghiglieri V, Picconi B (2007) Neuronal networks and synaptic plasticity in Parkinson's disease: beyond motor deficits. Parkinsonism Relat Disord 13(Suppl. 3):S259-S262. doi:10.1016/S1353-8020(08)70013-0
5. Cassarino DS, Fall CP, Swerdlow RH, Smith TS, Halvorsen EM, Miller SW, Parks JP, Parker WD, Bennett JP (1998) Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim Biophys Acta 1362:77-86. doi:10.1016/S0925-4439(97)00070-7
6. Chao CC, Hu S, Molitor TW, Shaskan EG, Peterson PK (1992) Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J Immunol 149:2736-2741
7. Chase TN, Oh JD (2000) Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci 23(Suppl. 1):S86-S91. doi:10.1016/S1471-1931(00)00018-5
8. Floden AM, Li S, Combs CK (2005) Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors. J Neurosci 25:2566-2575. doi:10.1523/JNEUROSCI.4998-04.2005
9. Hunot S, Boissière F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, Hirsch EC (1996) Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 72:355-363. doi:10.1016/0306-4522(95)00578-1
10. Johnson KA, Conn PJ, Niswender CM (2009) Glutamate receptors as therapeutic targets for Parkinson's disease. CNS Neurol Disord Drug Targets 8:475-491. doi:10.2174/187152709789824606
11. Juszczak GR, Swiergiel AH (2009) Properties of gap junction blockers and their behavioural, cognitive and electrophysiological effects: animal and human studies. Prog Neuropsychopharmacol Biol Psychiatry 33:181-198. doi:10.1016/j.pnpbp.2008. 12.014
12. Kreutzberg GM (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosciences 19:312-318. doi:10.1016/0166- 2236(96)10049-7
13. Laird DW (2010) The gap junction proteome and its relationship to disease. Trends Cell Biol 20:92-101. doi:10.1016/j.tcb.2009.11. 001
14. Nagatsu T, Sawada M (2006) Cellular and molecular mechanisms of Parkinson's disease: neurotoxins, causative genes, and inflammatory cytokines. Cell Mol Neurobiol 26:781-802. doi:10.1007/ s10571-006-9061-9
15. Nagatsu T, Mogi M, Ichinose H, Togari A (2000) Cytokines in Parkinson's disease. J Neural Transm Suppl 58:143-151. doi:10. 1007/978-3-7091-6284-2_12
16. Nelson PT, Soma LA, Lavi E (2002) Microglia in disease of the central nervous system. Ann Med 34:491-500. doi:10.1080/ 078538902321117698
17. Ransohoff RM, Perry VH (2009) Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 27:119-145. doi:10.1146/annurev.immunol.021908.132528
18. Sawada M, Suzumura A, Marunouchi T (1995) Cytokine network in the central nervous system and its roles in growth and differentiation of glial and neuronal cells. Int J Dev Neurosci 13:253-264. doi:10.1016/0736-5748(94)00076-F
19. Shen W, Flajolet M, Greengard P, Surmeier DJ (2008) Dichotomous dopaminergic control of striatal synaptic plasticity. Science 321:848-851. doi:10.1126/science.1160575
20. Suzuki H, Imai F, Kanno T, Sawada M (2001) Preservation of neurotrophin expression in microglia that migrate into the gerbil's brain across the blood-brain barrier. Neurosci Lett 312:95-98. doi:10.1016/S0304-3940(01)02198-X
21. Takeuchi H, Mizuno T, Zhang G, Wang J, Kawanokuchi J, Kuno R, Suzumura A (2005) Neuritic beading induced by activated microglia is an early feature of neuronal dysfunction toward neuronal death by inhibition of mitochondrial respiration and axonal transport. J Biol Chem 280:10444-10454. doi:10.1074/ jbc.M413863200
22. Takeuchi H, Jin S, Wang J, Zhang G, Kawanokuchi J, Kuno R, Sonobe Y, Mizuno T, Suzumura A (2006) Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J Biol Chem 28:21362-21368. doi:10.1074/jbc.M600504200
23. Takeuchi H, Jin S, Suzuki H, Doi Y, Liang J, Kawanokuchi J, Mizuno T, Sawada M, Suzumura A (2008) Blockade of microglial glutamate release protects against ischemic brain injury. Exp Neurol 214:144-146. doi:10.1016/j.expneurol.2008.08.001
24. Takeuchi H, Mizoguchi H, Doi Y, Jin S, Noda M, Liang J, Li H, Zhou Y, Mori R, Yasuoka S, Li E, Parajuli B, Kawanokuchi J, Sonobe Y, Sato J, Yamanaka K, Sobue G, Mizuno T, Suzumura A (2011) Blockade of gap junction hemichannel suppresses disease progression in mouse models of amyotrophic lateral sclerosis and Alzheimer's disease. PLoS One 6:e21108. doi:10.1371/ journal.pone.0021108
25. Vilhardt F, Plastre O, Sawada M, Suzuki K, Wiznerowicz M, Kiyokawa E, Trono D, Krause KH (2002) The HIV-1 Nef protein and phagocyte NADPH oxidase activation. J Biol Chem 277:42136-42143. doi:10.1074/jbc.M200862200
26. Zou JY, Crews FT (2005) TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition. Brain Res 1034:11-24. doi:10.1016/j.brainres.2004.11.014